These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers. Johnson S; Baraboutis JG JAMA; 2000 Dec; 284(21):2722-3. PubMed ID: 11105175 [No Abstract] [Full Text] [Related]
4. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers. Sha BE; Proia LA; Kessler HA JAMA; 2000 Dec; 284(21):2723. PubMed ID: 11105176 [No Abstract] [Full Text] [Related]
5. From the Centers for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000. JAMA; 2001 Jan 24-31; 285(4):402-3. PubMed ID: 11263401 [No Abstract] [Full Text] [Related]
7. Adverse effects of nevirapine. Das S; Allan PS; Wade AA Lancet; 2001 Aug; 358(9280):506; author reply 506. PubMed ID: 11515514 [No Abstract] [Full Text] [Related]
8. Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1. Benn PD; Mercey DE; Brink N; Scott G; Williams IG Lancet; 2001 Mar; 357(9257):687-8. PubMed ID: 11247556 [TBL] [Abstract][Full Text] [Related]
9. Tolerance of a short course of nevirapine, associated with 2 nucleoside analogues, in postexposure prophylaxis of HIV. Rey D; Partisani M; Hess-Kempf G; Krantz V; Priester M; Cheneau C; Bernard-Henry C; de Mautort E; Decroix L; Lang JM J Acquir Immune Defic Syndr; 2004 Dec; 37(4):1454-6. PubMed ID: 15602122 [TBL] [Abstract][Full Text] [Related]
10. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2001 Jan; 49(51-52):1153-6. PubMed ID: 11198946 [TBL] [Abstract][Full Text] [Related]
12. Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine. Shahar E; Krivoy N; Weltfriend S; Pollack S Jpn J Infect Dis; 2004 Oct; 57(5):212-3. PubMed ID: 15507779 [TBL] [Abstract][Full Text] [Related]
13. Hepatotoxicity after prophylaxis with a nevirapine-containing antiretroviral regimen. Johnson S; Chan J; Bennett CL Ann Intern Med; 2002 Jul; 137(2):146-7. PubMed ID: 12118982 [No Abstract] [Full Text] [Related]
14. Nevirapine should not be prescribed for needlestick injuries. Gottlieb S BMJ; 2001 Jan; 322(7279):126. PubMed ID: 11159560 [No Abstract] [Full Text] [Related]
15. Human immunodeficiency virus-infected boy with Stevens-Johnson syndrome caused by nevirapine. Tebruegge M; Ritz N; Connell T; Curtis N Pediatr Infect Dis J; 2008 Nov; 27(11):1041-2. PubMed ID: 18833024 [No Abstract] [Full Text] [Related]
16. Nevirapine to prevent HIV transmission via breastfeeding. Phadke MA; Bulakh PM; Kshirsagar NA Lancet; 2008 Jul; 372(9635):287. PubMed ID: 18657698 [No Abstract] [Full Text] [Related]
17. Tolerability of HIV postexposure prophylaxis among healthcare workers. Kiertiburanakul S; Wannaying B; Tonsuttakul S; Kehachindawat P; Apivanich S; Somsakul S; Malathum K J Hosp Infect; 2006 Jan; 62(1):112-4. PubMed ID: 16099546 [No Abstract] [Full Text] [Related]
18. Most common prescribing error in postexposure prophylaxis of HIV/AIDS. Mahajan A; Sharma H; Bhagat A; Tandon VR; Sharma R; Sharma S J Assoc Physicians India; 2007 Mar; 55():246-7. PubMed ID: 17598343 [No Abstract] [Full Text] [Related]
19. Reports on nevirapine threaten public health. Lane HC; Folkers GK; Fauci AS Nat Med; 2005 Mar; 11(3):245. PubMed ID: 15746930 [No Abstract] [Full Text] [Related]
20. Postexposure prophylaxis for human immunodeficiency virus at San Francisco General Hospital. Gerberding JL Am J Med; 1997 May; 102(5B):85-9. PubMed ID: 9845504 [No Abstract] [Full Text] [Related] [Next] [New Search]